Choosing between DOACs and VKAs could make a significant impact on patient outcomes, according to new findings published in the Journal of the American College of Cardiology.

However, the popular anti-inflammatory drug was linked to at least one other clinical benefit cardiologists should know about. 

The popular drugs, originally developed to treat diabetes, are being used more and more in the United States to help obese and overweight patients lose weight.  

Improving care for patients with cardiac amyloidosis has emerged as one of the hottest topics in cardiology. Pfizer helped kickstart that trend in 2019 when it gained FDA approval for two separate medications for the rare, but potentially fatal disease. 

The news comes as more and more medications, including Lilly's own tirzepatide, are being used to treat both obesity and diabetes. 

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

Medtronic confirmed its decision in a statement, but did not provide any specific details. The deal was originally announced in May.

The popular SGLT2 inhibitor, sold under the brand name Farxiga, is approved by the FDA to treat heart failure, type 2 diabetes and CKD. Recent data on its ability to affect the symptoms of heart failure patients have been inconsistent.